Skip to main content

Table 1 Baseline characteristics (ITT population)

From: Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study

  

All N = 35

Masitinib N = 27

Placebo N = 8

Age (years)

Mean ± SD

48 ± 8

49 ± 9

47 ± 7

 

Min - Max

29–61

29–61

33–56

Weight (kg)

Mean ± SD

69 ± 19

67 ± 19

74 ± 20

 

Min - Max

43–140

43–140

54–108

Male

N (%)

17 (49)

13 (48)

4 (50)

Duration of disease (years)

Mean ± SD

9.4 ± 7.4

9.5 ± 7.3

8.8 ± 8.4

 

Min - Max

0.2-28.6

0.2-28.6

1.5-25.6

MSFC score

Mean ± SD

0.0 ± 0.7

-0.1 ± 0.7

0.3 ± 0.8

9-HPT (seconds)

Mean ± SD

30 ± 9

30 ± 9

31 ± 12

PASAT-3” (correct answers)

Mean ± SD

31 ± 15

30 ± 15

36 ± 15

T25FW*

Mean ± SD

N/A

N/A

N/A

EDSS score

Mean ± SD

4.9 ± 1.2

4.9 ± 1.2

5.0 ± 1.1

  1. * The baseline average of the raw (seconds) timed 25-foot walk test was not applicable (N/A) because of the protocol deviation (see text for details). MSFC = multiple sclerosis functional composite score. N = number of patients, intent-to-treat population. T25FW = timed 25-foot walk test. 9-HPT = nine ­hole peg test. PASAT-3” = Paced Auditory Serial Addition Test 3 seconds. EDSS = expanded disability status scale. ITT = intent-to-treat.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us